COMUNICADO: Takeda Submits European Marketing Authorisation Application for Azilsartan Medoxomil, an Investigational Compound for th

Actualizado 20/10/2010 11:05:39 CET


Contacts:
Julia Ellwanger
Takeda Pharmaceuticals, Inc.
+1-224-554-7681
julia.ellwanger@tpna.com
Corporate Communications Dept.
Takeda Pharmaceutical Company Limited
+81-3-3278-2037
Helen Rae
Packer Forbes
+44-(0)20-7036-8550
helen@packerforbes.com
Rob Gallo
Takeda Pharmaceuticals Europe Ltd
+44-203-116-8874
robert.gallo@tpeu.co.uk

CONTACT: Contacts: Julia Ellwanger, Takeda Pharmaceuticals, Inc.,+1-224-554-7681, julia.ellwanger@tpna.com. Corporate Communications Dept.,Takeda Pharmaceutical Company Limited, +81-3-3278-2037. Helen Rae, PackerForbes, +44-(0)20-7036-8550, helen@packerforbes.com. Rob Gallo, TakedaPharmaceuticals Europe Ltd, +44-203-116-8874, robert.gallo@tpeu.co.uk

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación